Summary:
A systematic review indicates that women with polyendocrine metabolic ovarian syndrome (PMOS, formerly known as PCOS) face a heightened vulnerability to memory impairment, executive dysfunction, and neurodegenerative decline. The elevated risk for Alzheimer’s disease and dementia appears primarily driven by shared metabolic comorbidities, notably chronic insulin resistance and obesity.
Key Facts:
- Global Prevalance & Neurocognitive Deficits: PMOS impacts 10% to 15% of women worldwide, and clinical evaluations consistently document mild but reproducible impairments in executive functioning, memory, and structural brain connectivity.
- Metabolic Conduit to Dementia: The apparent association between PMOS and Alzheimer’s disease is largely mediated by downstream metabolic disorders, chiefly insulin resistance and obesity, rather than functioning as an independent endocrine driver.
- Therapeutic Crossover Potential: Because systemic metabolic dysregulation links the endocrine condition to brain pathology, targeted interventions for metabolic syndrome could provide dual protection against long-term neurodegeneration.
Source: Endocrine Society / University of Alabama at Birmingham
Affecting an estimated 10% to 15% of women globally, polyendocrine metabolic ovarian syndrome (PMOS), historically termed polycystic ovary syndrome (PCOS), is well recognized for its reproductive and metabolic impacts, including infertility, endometrial cancer, type 2 diabetes, cardiovascular disease, and stroke.
However, mounting clinical and neurological evidence indicates that its physiological reach extends into the central nervous system.
In a comprehensive review published in the Journal of the Endocrine Society, an international research team evaluated the complex intersections between PMOS and neurodegeneration. Their analysis suggests that individuals diagnosed with the endocrine syndrome face an elevated risk of developing cognitive decline, Alzheimer’s disease, and related dementias later in life.
Cognitive Changes and Brain Alterations
While long treated as an ovarian and metabolic condition, PMOS frequently presents with subtle neuropsychiatric and cognitive dimensions, including elevated rates of anxiety and depression.
Upon surveying biomedical literature across PubMed from inception through late 2025, investigators observed a consistent pattern: patients with PMOS exhibit reproducible deficits in executive function, working memory, and cognitive flexibility, accompanied by demonstrable structural and functional alterations within the brain.
Yet, despite these neurocognitive changes, the authors emphasize that PMOS does not necessarily directly trigger neurodegeneration on its own.
“Clinically, PMOS patients exhibit mild but reproducible impairments in executive function and memory, alongside structural and functional brain alterations, which could suggest greater risk for Alzheimer’s disease and dementia,” explained co-author Ricardo Azziz, MD, MPH, MBA, of the University of Alabama at Birmingham. “Current evidence suggests that any association between PMOS and Alzheimer’s disease and dementia is likely mediated by metabolic comorbidities, particularly insulin resistance and obesity, rather than an independent effect of PMOS itself.”
The Insulin Resistance Bridge
The connection between PMOS and Alzheimer’s disease reinforces the growing scientific consensus that metabolic dysregulation plays a central role in neurodegeneration—a dynamic often described in neuroscience as brain insulin resistance or “type 3 diabetes.”
In PMOS, peripheral cells become resistant to insulin, forcing the pancreas to produce excess hormone. Over decades, systemic hyperinsulinemia and chronic low-grade inflammation impair glucose transport across the blood-brain barrier. Deprived of efficient metabolic fuel, vulnerable cerebral regions, especially the hippocampus and frontal cortex, become increasingly susceptible to synaptic failure, tau hyperphosphorylation, and amyloid-beta accumulation.
Because obesity and metabolic syndrome frequently co-occur with PMOS, these shared biological pathways magnify the brain’s long-term vulnerability to neurodegenerative processes.
Clarifying Knowledge Gaps and Next Steps
The authors emphasize that significant questions remain, as longitudinal studies directly tracking dementia incidence in aging PMOS cohorts over multiple decades are still scarce. Furthermore, because PMOS features a wide spectrum of phenotypic presentations, determining how specific hormonal and metabolic profiles influence individual risk remains a key priority.
“Understanding how these two disorders that significantly impact women’s health worldwide are inter-related presents the opportunity to not only understand what these two very important morbidities have in common but also to discover new pathways and causes which could guide the development of novel treatments for these devastating diseases,” Azziz noted.
By highlighting metabolic control as the linchpin connecting ovarian and cognitive health, the researchers urge clinicians to consider proactive metabolic management in early adulthood not only for cardiovascular and reproductive health, but as a long-term defense against dementia.
Funding: The study was funded by the Foundation for Research and Education Excellence.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this dementia Research:
- Media Contact: Colleen Williams
- Source: Endocrine Society
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Journal of the Endocrine Society (Oct 1, 2026). “Potential links between PCOS/PMOS and Alzheimer disease and related dementias.” Authors: Mina Amiri, Armita Kakavand Hamidi, Daniel L. Farkas, Richard P. Buyalos, and Ricardo Azziz.
- DOI: 10.1210/jendso/bvag206
Abstract
Potential links between PCOS/PMOS and Alzheimer disease and related dementias
Background
Polycystic ovary syndrome/polyendocrine metabolic ovarian syndrome (PCOS/PMOS) is a common endocrine disorder with significant metabolic and reproductive implications. Increasing attention has focused on its potential long-term neurological consequences, including possible links to cognitive impairment and Alzheimer disease (AD), through overlapping biological pathways.
Methods
We conducted a comprehensive PubMed search, from inception through October 2025, identifying studies on cognitive performance, brain structure and function, neurodegenerative biomarkers, and dementia risk in PCOS/PMOS patients.
Results
Evidence supports multiple potential mechanistic pathways that could connect PCOS/PMOS to AD-relevant biology, such as insulin resistance (IR), chronic inflammation, hormonal dysregulation, and cardiovascular dysfunction. These pathways converge on neurodegeneration processes such as impaired Aβ clearance, tau hyperphosphorylation, oxidative stress, and cerebral metabolic deficits.
Clinically, PCOS/PMOS patients exhibit mild but reproducible impairments in executive function and memory, alongside structural and functional brain alterations, including hippocampal and white matter changes, and altered network connectivity. However, these findings are influenced by coexisting metabolic dysfunction, and direct epidemiological evidence linking PCOS/PMOS to increased dementia incidence remains limited and inconsistent.
Conclusion
Current evidence indicates that any association between PCOS/PMOS and AD risk is likely mediated by metabolic comorbidities, particularly IR and obesity, rather than an independent effect of PCOS/PMOS itself. However, clinical evidence for increased PCOS/PMOS risk for cognitive vulnerability and dementia remain inconsistent and cognitive benefits from PCOS/PMOS-specific interventions are lacking. Clinical focus should therefore remain on optimizing metabolic health, while longitudinal and interventional studies are required to clarify long-term neurological relationships and outcomes.
